Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | TACR1 | P25103 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | THPO | P40225 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | GMNN | O75496 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15517626 | 1.00 | CYP1A2 (0.51) | CYP1A2CYP2D6CYP2C19KDM4ENPC1 | |
| SCHEMBL5536844 | 0.89 | CYP1A2 (0.58) | CYP1A2CYP2D6CYP2C19KDM4ENPC1 | |
| SCHEMBL3008035 | 0.89 | CYP1A2 (0.58) | CYP1A2CYP2D6CYP2C19KDM4ENPC1 | |
| SCHEMBL3008034 | 0.89 | CYP1A2 (0.58) | CYP1A2CYP2D6CYP2C19KDM4ENPC1 | |
| SCHEMBL15281197 | 0.85 | CYP1A2 (0.51) | CYP1A2CYP2D6CYP2C19KDM4ENPC1 | |
| SCHEMBL15281063 | 0.85 | CYP1A2 (0.51) | CYP1A2CYP2D6CYP2C19KDM4ENPC1 | |
| SCHEMBL20128490 | 0.85 | CYP1A2 (0.51) | CYP1A2CYP2D6CYP2C19KDM4ENPC1 | |
| SCHEMBL10326924 | 0.83 | CYP1A2 (0.50) | CYP1A2CYP2D6CYP2C19KDM4ENPC1 | |
| SCHEMBL10327087 | 0.83 | CYP1A2 (0.50) | CYP1A2CYP2D6CYP2C19KDM4ENPC1 | |
| SCHEMBL10326851 | 0.83 | CYP1A2 (0.50) | CYP1A2CYP2D6CYP2C19KDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192682-A1 | IMPROVED SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. | 2023-06-22 | — | — | US | claimed |
| EP-4058432-A1 | IMPROVED SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | Amgen Inc. (US) | 2022-09-21 | — | — | EP | claimed |
| WO-2021097207-A1 | IMPROVED SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. (US) | 2021-05-20 | — | — | WO | claimed |
| EP-4308228-A1 | PLASMA KALLIKREIN INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2024-01-24 | — | — | EP | disclosed |
| US-20230192682-A1 | IMPROVED SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. | 2023-06-22 | — | — | US | disclosed |
| EP-4058432-A1 | IMPROVED SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | Amgen Inc. (US) | 2022-09-21 | — | — | EP | disclosed |
| WO-2021097207-A1 | IMPROVED SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| US-20190127306-A1 | POLYCYCLIC CARBOGENIC MOLECULES AND USES THEREOF AS ANTI-CANCER AGENTS | NORTHWESTERN UNIVERSITY (US) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192682-A1 | IMPROVED SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | KRAS, NRAS, HRAS | CYP1A2 4074/4885CYP2D6 3132/4885CYP2C19 2185/4885 |
| US-20190127306-A1 | POLYCYCLIC CARBOGENIC MOLECULES AND USES THEREOF AS ANTI-CANCER AGENTS | MYC, CDK4, CDKL3 | CYP1A2 3279/4885CYP2D6 4035/4885CYP2C19 2920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.